Holen Sie sich die Stockscreener-App
96.50
0.77%
-0.78
Schlusskurs vom Vortag:
$97.28
Offen:
$97.5
24-Stunden-Volumen:
1.19M
Relative Volume:
1.16
Marktkapitalisierung:
$23.21B
Einnahmen:
$3.13B
Nettoeinkommen (Verlust:
$-381.72M
KGV:
-60.25
EPS:
-1.6017
Netto-Cashflow:
$-2.15B
1W Leistung:
+0.44%
1M Leistung:
-6.41%
6M Leistung:
-11.42%
1J Leistung:
-20.10%
1-Tages-Spanne:
$95.04
$97.69
1-Wochen-Bereich:
$95.04
$99.56
52-Wochen-Spanne:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
96.53 | 23.39B | 3.13B | -381.72M | -2.15B | -1.6017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.67 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.31 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.10 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.79 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
Dodge & Cox Invests $93.42 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group - Defense World
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules - Yahoo Finance
Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/1/2025 - Nasdaq
Groupama Asset Managment Buys 26,681 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Employees Retirement System of Texas Has $1.69 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Legal & General Group Plc Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Purchases 2,826 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE ADR Rises 3.0%, Outperforms Market - 富途牛牛
Edmond DE Rothschild Holding S.A. Raises Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Purchased by CenterBook Partners LP - MarketBeat
AXQ Capital LP Acquires 1,073 Shares of Strategy Inc $MSTR - Defense World
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
Allworth Financial LP Grows Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
BioNTech Faces Strategic Crossroads as Pfizer Reduces Stake () - aktiencheck.de
Total debt per share of BioNTech SE Sponsored ADR – BER:22UA - TradingView
SG Americas Securities LLC Acquires 51,792 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ - Finviz
BioNTech’s Earnings Call: Progress Amid Challenges - MSN
Pfizer Scales Back Major Stake in BioNTech - Ad-hoc-news.de
BioNTech Shares Under Pressure as Key Investor Exits - AD HOC NEWS
Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech Shares Face Pressure as Pfizer Cuts Stake () - aktiencheck.de
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up By Reuters - Investing.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is BioNTech Stock Building Momentum for a Sustained Recovery? () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE Reports Q3 2025 Financial Results - MSN
BioNTech Earnings: Steady Progress in Next-Generation Oncology Pipeline; Guidance Raised - Morningstar
BioNTech Q3 2025 Earnings Call Transcript - MarketBeat
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech Faces Critical Earnings Test Amid Divergent Forecasts () - aktiencheck.de
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
BioNTech’s Promising Study on BNT113 and Pembrolizumab for Head and Neck Cancer - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):